News and Events

Nirali Shah, Benedict Anchang, and Sadhana Jackson

CCR researchers receive Presidential Early Career Awards for Scientists and Engineers

Three CCR researchers received the Presidential Early Career Award for Scientists and Engineers (PECASE), one of the highest honors bestowed by the U.S. Government to outstanding scientists and engineers.

Natasha Caplen appointed to Senior Investigator at CCR

The CCR community congratulates Natasha J. Caplen, Ph.D., who has been appointed Senior Investigator in the Genetics Branch. Caplen contributed to the discovery of RNA interference (RNAi) in mammalian cells and has pioneered approaches for exploiting this gene regulatory mechanism to investigate cancer biology and treatment. Her current studies focus on the functional genetic analysis of cancers driven by fusion oncogenes, particularly the pediatric tumor Ewing sarcoma.

Targeting two proteins leaves some cancer cells vulnerable to chemotherapy

Targeting two proteins that cancer cells rely on to sustain their metabolism and DNA repair capabilities can double the survival rate of mice with lung cancer tumors. Cross referencing with data from The Cancer Genome Atlas of human tumors suggests that these findings could translate to people.

DNA breakage and synthesis in the cell nucleus

Research uncovers a novel mechanism for cells to recover from DNA damage

A newly discovered cellular mechanism sheds light on how cancer cells proliferate despite damage from anti-cancer treatments, providing a target for new therapies.

Celebrating CCR Careers: Patricia S. Steeg, Ph.D.

Patricia S. Steeg, Ph.D., who discovered the first metastasis suppressor gene, nm23, announces her retirement.

An illustration of papillomas in the throat

Innovative gene therapy shows promise in treating patients with recurrent respiratory papillomatosis

A clinical trial led by CCR researchers demonstrated the effectiveness of the novel treatment, PRGN-2012, against recurrent respiratory papillomatosis in adults. The results serve as the foundation for an application for accelerated approval to the U.S. Food and Drug Administration (FDA).

Image of the BRCA2 protein with a sliding scale of color indicating the regions containing certain variants. Blue regions contain benign variants, while red regions contain pathogenic regions.

Researchers categorize thousands of BRCA2 mutations as cancerous or benign

Researchers used CRISPR gene editing technology to determine whether over 6,000 variants of BRCA2 were likely to cause cancer.

Nirali Shah elected to the American Society for Clinical Investigation

Nirali N. Shah, M.D., M.H.Sc., Lasker Clinical Research Scholar in the Pediatric Oncology Branch, was elected as a member of the American Society for Clinical Investigation (ASCI). The organization seeks to support the scientific efforts, educational needs, and clinical aspirations of physician-scientists to improve the health of all people. The 2025 newly elected members came from 46 different institutions and represent excellence across the breadth of academic medicine.

Clinical trial researching immunotherapy for solid tumors

A clinical trial led by Danielle M. Pastor, D.O., Ph.D., Assistant Research Physician in the Center for Immuno-Oncology, is researching immunotherapy for adults with advanced solid tumors.

Clinical trial researching combination drug therapy for neuroendocrine carcinomas

A clinical trial led by Jaydira Del Rivero, M.D., Associate Research Physician in the Developmental Therapeutics Branch, is researching combination drug therapy for adults with high-grade neuroendocrine carcinomas.

Breadcrumb